Q3 EPS Forecast for Ovid Therapeutics Decreased by Analyst

Key Points

• HC Wainwright has revised its earnings estimates for Ovid Therapeutics, projecting a Q3 2025 EPS of ($0.13), down from a prior estimate of ($0.12), while maintaining a "Buy" rating with a target price of $1.50.
• Ovid Therapeutics recently reported a quarterly EPS of ($0.06), exceeding consensus estimates, and generated revenue of $6.27 million, significantly higher than the estimated $0.09 million.
• Institutional ownership of Ovid Therapeutics remains strong, with 72.24% of the stock held by hedge funds and significant increases in holdings by firms like Bank of America and Renaissance Technologies.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share estimates for Ovid Therapeutics in a research report issued on Monday, August 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.13) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright has a "Buy" rating and a $1.50 price target on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics' FY2025 earnings at ($0.46) EPS.

A number of other research firms have also recently commented on OVID. B. Riley reiterated a "buy" rating and set a $3.00 price objective on shares of Ovid Therapeutics in a research report on Friday, August 8th. Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $3.10.

Ovid Therapeutics Stock Performance

Ovid Therapeutics stock traded up $0.03 during mid-day trading on Wednesday, reaching $1.28. 1,865,154 shares of the stock traded hands, compared to its average volume of 1,840,068. The stock has a market capitalization of $91.02 million, a PE ratio of -2.42 and a beta of 0.34. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.72 and a quick ratio of 4.72. Ovid Therapeutics has a 12-month low of $0.24 and a 12-month high of $1.47. The business's 50-day moving average is $0.63 and its 200-day moving average is $0.46.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.10. The company had revenue of $6.27 million during the quarter, compared to analysts' expectations of $0.09 million. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%.

Institutional Trading of Ovid Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its position in shares of Ovid Therapeutics by 49.7% during the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company's stock worth $53,000 after purchasing an additional 18,841 shares in the last quarter. Velan Capital Investment Management LP grew its position in shares of Ovid Therapeutics by 64.9% during the second quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company's stock worth $53,000 after purchasing an additional 63,000 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Ovid Therapeutics by 142.0% during the fourth quarter. Renaissance Technologies LLC now owns 107,700 shares of the company's stock worth $101,000 after purchasing an additional 63,200 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Ovid Therapeutics during the first quarter worth about $29,000. Finally, Nuveen LLC purchased a new stake in shares of Ovid Therapeutics during the first quarter worth about $37,000. Hedge funds and other institutional investors own 72.24% of the company's stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.